fosbretabulin

Phase 3Small molecule

fosbretabulin is one of 113 small molecule programs targeting Polypoidal choroidal vasculopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polypoidal Choroidal VasculopathyActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Thyroid CancerActive, not recruiting

Polypoidal Choroidal VasculopathyPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2/Phase 3

Active, not recruiting

Thyroid CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

fosbretabulin

MMateon Therapeutics

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroendocrine Tumors2 trials

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Terminated·LLowell Anthony, MD·Phase 1·NCT03014297·17 enrolled

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Completed·MMateon Therapeutics·Phase 2·NCT02132468·18 enrolled

Ovarian Cancer2 trials

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Terminated·MMateon Therapeutics·Phase 2/3·NCT02641639·70 enrolled

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Terminated·TThe Christie NHS Foundation Trust·Phase 1/2·NCT02055690·21 enrolled

Polypoidal choroidal vasculopathy1 trial

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Completed·MMateon Therapeutics·Phase 2·NCT01023295·20 enrolled

Phase 21 trial

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Completed·MMateon Therapeutics·Phase 2·NCT02279602·7 enrolled

Non-Small Cell Lung Cancer1 trial

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Completed·MMateon Therapeutics·Phase 2·NCT00653939·63 enrolled

2 more indications

Thyroid Cancer1 trial

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

Withdrawn·MMateon Therapeutics·Phase 3·NCT01701349

Fallopian Tube1 trial

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01305213·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for fosbretabulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fosbretabulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fosbretabulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mateon Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMateon Therapeutics

fosbretabulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroendocrine Tumors2 trials

Ovarian Cancer2 trials

Polypoidal choroidal vasculopathy1 trial

Phase 21 trial

Non-Small Cell Lung Cancer1 trial

Thyroid Cancer1 trial

Fallopian Tube1 trial

References

Drug Info

Quick Facts

Related News